Connect with us

Uncategorized

Drug delivery platform uses sound for targeting

Chemotherapy as a treatment for cancer is one of the major medical success stories of the 20th century, but it’s far from perfect. Anyone who has been…

Published

on

Chemotherapy as a treatment for cancer is one of the major medical success stories of the 20th century, but it’s far from perfect. Anyone who has been through chemotherapy or who has had a friend or loved one go through it will be familiar with its many side effects: hair loss, nausea, weakened immune system, and even infertility and nerve damage.

Credit: Caltech

Chemotherapy as a treatment for cancer is one of the major medical success stories of the 20th century, but it’s far from perfect. Anyone who has been through chemotherapy or who has had a friend or loved one go through it will be familiar with its many side effects: hair loss, nausea, weakened immune system, and even infertility and nerve damage.

This is because chemotherapy drugs are toxic. They’re meant to kill cancer cells by poisoning them, but since cancer cells derive from healthy cells and are substantially similar to them, it is difficult to create a drug that kills them without also harming healthy tissue.

But now a pair of Caltech research teams have created an entirely new kind of drug-delivery system, one that they say may finally give doctors the ability to treat cancer in a more targeted way. The system employs drugs that are activated by ultrasound—and only right where they are needed in the body.

The system was developed in the labs of Maxwell Robb, assistant professor of chemistry, and Mikhail Shapiro, Max Delbrück Professor of Chemical Engineering and Medical Engineering and Howard Hughes Medical Institute investigator. In a paper appearing in the journal Proceedings of the National Academy of Sciences, the researchers show how they combined elements from each of their specialties to create the platform.

Working collaboratively, the two research teams married gas vesicles (air-filled capsules of protein found in some bacteria) and mechanophores (molecules that undergo a chemical change when subjected to physical force). Shapiro’s lab has previously used gas vesicles in conjunction with ultrasound to image individual cells and precisely move cells around. Robb’s lab, for its part, has created mechanophores that change color when stretched, making them useful for detecting strain in structures, and other mechanophores that can release a smaller molecule, including a drug, in response to a mechanical stimulus. For the new work, they devised a way to use ultrasound waves as that stimulus.

“We’ve been thinking about this for a really long time,” Robb says. “It started when I first came to Caltech and Mikhail and I started having conversations about the mechanical effects of ultrasound.”

As they began researching the combination of mechanophores and ultrasound, they discovered a problem: Ultrasound could activate the mechanophores, but only at an intensity so strong that it also damaged neighboring tissues. What the researchers needed was a way to focus the energy of the ultrasound right where they wanted it. It turned out that Shapiro’s gas vesicle technology provided the solution.

In his previous work, Shapiro made use of the vesicles’ tendency to vibrate or “ring” like a bell when bombarded with ultrasound waves. In the current research, however, the vesicles are rung so hard that they break, which focuses the ultrasound energy. The vesicles effectively become tiny bombs whose explosions activate the mechanophore.

“Applying force through ultrasound usually relies on very intense conditions that trigger the implosion of tiny dissolved gas bubbles,” says Molly McFadden (PhD ’23), study co-author. “Their collapse is the source of mechanical force that activates the mechanophore. The vesicles have heightened sensitivity to ultrasound. Using them, we found the same mechanophore activation can be achieved under much weaker ultrasound.”

Yuxing Yao, a postdoctoral scholar research associate in Shapiro’s lab, says this is the first time that focused ultrasound has been able to control a specific chemical reaction in a biological setting.

“Previously ultrasound has been used to disrupt things or move things,” Yao says. “But now it’s opening this new path for us using mechanochemistry.”

So far, the platform has only been tested under controlled laboratory conditions, but in the future, the researchers plan to test it in living organisms.

The paper describing the research is titled “Remote Control of Mechanochemical Reactions Under Physiological Conditions Using Biocompatible Focused Ultrasound.” Additional co-authors are chemistry graduate student Stella M. Luo and Ross W. Barber (PhD ’23); Elin Kang (BS ’23); Avinoam Bar-Zion, formerly of Caltech and now with Technion-Israel Institute of Technology; Cameron A. B. Smith, postdoctoral scholar fellowship trainee in chemical engineering; medical engineering graduate student Zhiyang Jin (MS ’18); chemical engineering graduate student Mark Legendre; Bill Ling (PhD ’23), postdoctoral scholar research associate in chemical Engineering; Dina Malounda of the Howard Hughes Medical Institute; Caltech undergraduate students Andrea Torres and Tiba Hamza; and Chelsea E. R. Edwards, formerly of Caltech, now at UC Santa Barbara.

Funding for the research was provided by Arnold and Mabel Beckman Foundation, the David and Lucile Packard Foundation, the Resnick Sustainability Institute, the Institute for

Collaborative Biotechnologies, and the National Institute of General Medical Sciences of the National Institutes of Health.

 


Read More

Continue Reading

Uncategorized

VanEck Ethereum Futures ETF Debuts In The U.S.

The United States cryptocurrency sector received a jolt on Monday, as VanEck today marks the inaugural debut of its Ethereum-based exchange-traded fund…

Published

on

The United States cryptocurrency sector received a jolt on Monday, as VanEck today marks the inaugural debut of its Ethereum-based exchange-traded fund (ETF). The innovative investment instrument is designed to offer investors indirect exposure to the second-largest cryptocurrency by market capitalization. This exposure is achieved by investing in contracts of Ethereum (ETH) futures.

The product, listed on VanEck’s website, commenced trading on October 2nd on the Chicago Board Options Exchange (CBOE). This milestone establishes VanEck as one of the pioneering U.S. investment managers to introduce an ETF grounded in Ether futures—cash-settled ETH futures contracts traded on the Chicago Mercantile Exchange, a registered exchange supervised by the Commodity Futures Trading Commission (CFTC).

VanEck had disclosed its plans to launch an ETF based on Ether futures last week, indicating that it had received the eagerly awaited approval from the Securities and Exchange Commission (SEC).

Sign Up To The TDR Newsletter

The competition for Ethereum futures-based ETFs gained momentum earlier this year when several managers, including Bitwise, ProShares, VanEck, and Grayscale, submitted proposals for such products. As of the latest count, approximately 15 entities have submitted their proposals to the SEC this year.

While U.S. regulators greenlit the launch of the first ETFs based on Bitcoin futures in 2021, they had not previously endorsed funds tied to futures of other cryptocurrencies. VanEck, at that time, emerged as the second manager in the nation to introduce a BTC futures ETF.

In addition to VanEck’s Ethereum futures performance-focused product, several others also made their debut on this Monday. ProShares, the same company that introduced the first U.S. Bitcoin futures ETF in 2021, introduced the ProShares Ether Strategy ETF, along with two others offering a blend of BTC and ETH exposure. Bitwise, another manager, announced the launch of two ETH futures ETFs: the Bitwise Ethereum Strategy ETF and the Bitwise Bitcoin and Ether Equal Weight Strategy ETF.

The crypto community is still awaiting the introduction of the first spot ETFs for both Bitcoin and ETH. In August, the SEC delayed it decision to issue spot crypto ETFs, although no official reason was cited in the decision.

The post VanEck Ethereum Futures ETF Debuts In The U.S. appeared first on The Dales Report.

Read More

Continue Reading

Uncategorized

Study uncovers function of mysterious disordered regions of proteins implicated in cancer

Study uncovers function of mysterious disordered regions of proteins implicated in cancer Credit: Courtesy of Dana-Farber Cancer Institute Study uncovers…

Published

on

Study uncovers function of mysterious disordered regions of proteins implicated in cancer

Credit: Courtesy of Dana-Farber Cancer Institute

Study uncovers function of mysterious disordered regions of proteins implicated in cancer

Study Title: A disordered region controls cBAF activity via condensation and partner recruitment

Publication: Cell, Monday, October 2, 2023 (https://www.dana-farber.org/newsroom/news-releases/2023/study-uncovers-function-of-mysterious-disordered-regions-of-proteins-implicated-in-cancer/)

Dana-Farber Cancer Institute author: Cigall Kadoch, PhD

Summary:

New research from Dana-Farber Cancer Institute researcher Cigall Kadoch, PhD, along with colleagues at Princeton University and the Washington University in St. Louis, reveals a key role for intrinsically disordered proteins known as IDRs that are implicated in a wide range of human diseases, from cancer to neurodegeneration. Kadoch’s team studies large protein complexes called mSWI/SNF or BAF complexes that control which genes turn on and off in cells. BAF complexes are the most frequently mutated cellular entities, second only to TP53, a tumor suppressor. Intrigued by the fact that over half of the complex mass contains IDRs, including the ARID1A/B subunits in which a high frequency of disease-causing lesions, or mutations, accumulate, the group set out to define their contributions. They found that these IDR regions lead to two important functions: first, condensation, the tight clustering of proteins in close distance to one another in the nucleus, and second, protein-protein interactions that are required for the proper positioning and activity of BAF complexes along DNA. Kadoch and colleagues show that the right interactions depend on highly specific “sequence grammars” within the protein’s IDR amino acid code, a concept broadly useful to the burgeoning area of work in this area to understand and ultimately therapeutically target biomolecular condensates and their constituents.

Impact:

IDRs comprise a large percentage of the human proteome and are particularly important for nuclear proteins that govern our genomic architecture and gene expression. Their disruption is frequent in cancer. This study sheds light on the sequence-specific contributions of IDRs to the highly disease-relevant mSWI/SNF (BAF) chromatin remodeling complexes, which have become top therapeutic targets in oncology.

Funding:

Howard Hughes Medical Institute, The Mark Foundation, National Institutes of Health, United States Air Force Office of Scientific Research, St. Jude Research Collaboratives, Fujifilm, and The Wellcome Trust.

Contact:  Cindy Cantrell; cindy_cantrell@dfci.harvard.edu; 781-953-5000


Read More

Continue Reading

Uncategorized

Book describes Sam Bankman-Fried with little attention span or respect for appointments

The former FTX CEO was reportedly invited by Vogue editor-in-chief Anna Wintour to be her special guest at the Met Gala, only to cancel at the last minute….

Published

on

The former FTX CEO was reportedly invited by Vogue editor-in-chief Anna Wintour to be her special guest at the Met Gala, only to cancel at the last minute.

Michael Lewis, author of The Big Short, has painted an interesting picture of Sam Bankman-Fried (SBF) in his soon-to-be released book on the former FTX CEO.

In an excerpt of Going Infinite: The Rise and Fall of a New Tycoon published in the Washington Post on Oct. 1, Lewis described several interactions Bankman-Fried had with the media and influential figures prior to the downfall of FTX and his criminal charges in the United States. According to the author, he would frequently play video games in the background of online interviews — his League of Legends exploits are well reported — often giving little attention to people including Vogue editor-in-chief Anna Wintour.

“Sam didn’t want to seem rude,” said Lewis on SBF’s talk with Wintour. “It was just that he needed to be playing this other game at the same time as whatever game he had going in real life. His new social role as the world’s most interesting new child billionaire required him to do all kinds of dumb stuff. He needed something, other than what he was expected to be thinking about, to occupy his mind.”

Lewis added that Natalie Tien, who moved into the role of FTX’s head of public relations and SBF’s “personal scheduler”, said the former CEO cancelled many highly publicized appearances — often at the last minute — for seemingly no reason at all. The Wintour interview reportedly led to FTX's sponsorship and Bankman-Fried as a special guest at the Met Gala, which he ended up snubbing.

“Sam treated everything on his schedule as optional,” said the book. “The schedule was less a plan than a theory. When people asked Sam for his time, they assumed they’d posed a yes or no question [...] All he had done, when he said yes, was to assign some non-zero probability to the proposed use of his time. The dial would swing wildly as he calculated and recalculated the expected value of each commitment, right up until the moment he honored it or didn’t.”

Other in-person showings by Bankman-Fried included testifying before the U.S. House Financial Services Committee in December 2021 and meeting with Senator Mitch McConnell. The appearances marked some of the rare times SBF appeared in public wearing a suit as opposed to his usual T-shirt and shorts — though social media users pointed to footage of the then CEO's shoes slipped on without being tied at the hearing.

Related: Sam Bankman-Fried FTX trial — 5 things you need to know

It’s unclear what other information will become available once the book is released on Oct. 3, the same day jury selection begins for SBF’s criminal trial in New York. Amid the expected court proceedings, a slew of podcasts, news features, books, and other media have been released detailing aspects of Bankman-Fried’s life before and after the downfall of FTX. A 60 Minutes interview with Lewis revealed SBF had plans to pay off former U.S. President Donald Trump not to run for the office again based on the threat to elections and democracy as a whole.

On Oct. 4, Bankman-Fried will appear in a New York courtroom for the first day of his trial, scheduled to run through November. He will face 7 charges related to fraud at FTX and Alameda Research, for which he has pleaded not guilty.

Magazine: Can you trust crypto exchanges after the collapse of FTX?

Read More

Continue Reading

Trending